Selected SOCAR publications and presentations

Selected list of publications:

  • Andrew J Stewart Coats, Venkatesan Srinivasan, Jayaraman Surendran, Haritha Chiramana, Shankar R.K.G. Vangipuram, Nirajkumar Navinchandra Bhatt, Minish Jain, Sandip Shah, Irfhan Ali Bin Hyder Ali, Ho Gwo Fuang, Mohammed Zailani Mat Hassan, John Beadle Julia Tilson, Bridget-Anne Kirwan, Stefan D. Anker on behalf of the ACT-ONE Trial Investigators: The ACT-ONE TRIAL, a multicentre randomized, double-blind placebo-controlled dose finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design J cachexia Sarcopenia Muscle 2011 Dec, 2(4):201-207. Epub 2011 Oct 16
  • Friedrich Koehler, MD, Sebastian Winkler, MD, Michael Schieber, MD Udo Sechtem, MD, Karl Stangl, MD, Michael Böhm, MD, Sophie de Brouwer, PhD, Emilie Perrin, Gert Baumann, MD, Goetz Gelbrich, PhD, Herbert Boll, MD, Marcus Honold, MD, Kerstin Koehler, MD, Bridget-Anne Kirwan, PhD, Stefan D Anker, MD, PhD, on behalf of the TIM-HF Investigators: Telemedicine in heart failure: pre-specified and exploratory subgroup analyses from the TIM-HF trial - Int. J. Cardiol. 161, 143 (2012)
  • Friedrich Koehler, MD; Sebastian Winkler, MD; Michael Schieber, MD; Udo Sechtem, MD; Karl Stangl, MD; Michael Bohm, MD; Herbert Boll, MD; Gert Baumann, MD; Marcus Honold, MD; Kerstin Koehler, MD; Goetz Gelbrich, PhD; Bridget-Anne Kirwan, PhD; Stefan D. Anker, MD, PhD: Impact of Remote Telemedical Management on Mortality and Hospitalizations in Ambulatory Patients With Chronic Heart Failure The Telemedical Interventional Monitoring in Heart Failure Study: Circulation, 2011 May 3; 123 (17):1873-80
  • Zoltán Vokó, MD, PhD; Sophie de Brouwer, PhD; Jacobus Lubsen, MD, PhD; Nicolas Danchin, MD; Jan-Erik Otterstad, MD; Peter HJM Dunselman MD, PhD; Bridget-Anne Kirwan, PhD: Long-term impact of secondary preventive treatments in patients with stable angina. European Journal of Epidemiology: 02/2011;26 (5):375-83
  • Friedrich Koehler, MD, Sebastian Winkler, MD, Michael Schieber, MD, Udo Sechtem, MD, Karl Stangl, MD, Michael Böhm, MD, Herbert Boll, MD, Simone S Kim, MD, Kerstin Koehler, MD, Stephanie Lücke, Markus Honold, MD, Peter Heinze, Thomas Schweizer, Martin Braecklein, Bridget-Anne Kirwan, PhD, Goetz Gelbrich, PhD, Stefan D Anker, MD PhD: Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design – European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2010; 12(12): 1354-62
  • Bonnie Ky, MD, Bridget-Anne Kirwan, PhD; Sophie de Brouwer, PhD, Jacobus Lubsen, MD, PhD, Philip Poole-Wilson, MD, Jan-Erik Otterstad, MD Stephen E. Kimmel, MD; Martin St. John Sutton, MBBS: Gender Differences in Cardiac Remodeling and Clinical Outcomes in Chronic Stable Angina Patients (from the ACTION trial): The American journal of cardiology 2010; 105(7): 943-7
  • Stefan D. Anker, M.D., Ph.D., Josep Comin Colet, M.D., Gerasimos Filippatos, M.D., Ronnie Willenheimer, M.D.,Kenneth Dickstein, M.D., Ph.D., Helmut Drexler, M.D., Thomas F. Lüscher, M.D., Boris Bart, M.D., Waldemar Banasiak, M.D., Ph.D.,Joanna Niegowska, M.D., Bridget-Anne Kirwan, Ph.D., Claudio Mori, M.D.,Barbara von Eisenhart Rothe, M.D., Stuart J. Pocock, Ph.D., Philip A. Poole-Wilson, M.D., Piotr Ponikowski, M.D., Ph.D.,for the FAIR-HF Trial Investigators: Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N Engl J Med 2009; 361: 2436-48
  • Faiez Zannad, Wendy Gattis Stough, Bertram Pitt, John G.F. Cleland, Kirkwood F. Adams, Nancy L. Geller, Christian Torp-Pedersen, Bridget-Anne Kirwan, and Ferenc Follath: Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur. Heart J., February 2008; 29(3): 413-421
  • Bridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, Frederik J. van Dalen, Stuart J. Pocock, Tim Clayton, Nicolas Danchin, Philip A. Poole-Wilson, on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators: Quality management of a large randomized double-blind multi-centre trial: The ACTION experience: Contemp. Clin Trials. 2008 Mar; 29(2) 29 259-269
  • Zoltán Vokó; Nocolas Danchin; Sophie de Brouwer; Bridget-Anne Kirwan; Philip A Poole-Wilson; Jacobus Lubsen: Correlates of coronary angiography in patients with stable angina and geographical differences in its utilisation: the ACTION experience: Int J Cardiol 2008 Oct 7
  • Kirwan B-A, Lubsen J, de Brouwer S, Danchin N, Dunselman P, Sutton G, Battler A, Bayes de Luna A, Glasser S, Koudstaal P, van Dalen F, Poole-Wilson PA. Criteria and adjudication process both determine published event rates: The ACTION trial experience. Contemp Clin Trials 2007 Nov; 28(6): 720-729
  • Motro M, Kirwan B-A, de Brouwer S, Poole-Wilson PA, Shemesh J on behalf of the ACTION CC side-arm study. Tracking Coronary Calcification and Atherosclerotic Lesions in Patients with Stable Angina Pectoris Undergoing Nifedipine Therapy: Cardiology.2007; 107(3): 165-71
  • AM Dart, JE Otterstad, BA Kirwan, JD Parker, S de Brouwer, PA Poole-Wilson, J Lubsen, and ACTION investigators: Predictive value of local and core laboratory echocardiographic assessment of cardiac function in patients with chronic stable angina: The ACTION study. Eur J Echocardiogr. 2007 Aug; 8(4): 275-83
  • Sutton GC, Otterstad JE, Kirwan B-A, Vokó Z, de Brouwer S, Lubsen J, Poole-Wilson PA on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. The development of heart failure in patients with stable angina pectoris. Eur J Heart Fail. 2007; 107(3): 165-71
  • Poole-Wilson PA, Kirwan B-A, Vokó Z, de Brouwer S, Dunselman P, van Dalen F, Lubsen J on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Resource utilization implications of treatment was assessed when clinical trial data are reported appropriately: J Clin Epidemiol. 2007 Jul; 60(7): 720-6
  • Lubsen J, Voko Z, Poole-Wilson PA, Kirwan B-A, de Brouwer S on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Blood pressure reduction in stable angina by nifedipine was related to stroke and heart failure reduction but not to coronary interventions: J Clin Epidemiol.2007 Jul; 60(7): 720-6
  • Ruilope LM, Kirwan B-A, de Brouwer S, Danchin N, Fox KA, Wagener G, Segura J, Poole-Wilson PA, Lubsen J on behalf of the ACTION investigators. Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. J Hypertens 2007 Aug; 25(8): 1711-1718
  • Poole-Wilson PA, Voko Z, Kirwan B-A, de Brouwer S, Dunselman P, Lubsen J for the ACTION investigators. Clinical course of isolated stable angina due to coronary heart disease: Eur Heart J. 2007 Aug; 28(16): 1928-35
  • Otterstad JE, Kirwan B-A, Lubsen J, de Brouwer S, Fox KA, Corell P, Poole-Wilson PA on behalf of the action investigators. Incidence and outcome of atrial fibrillation in stable symptomatic Coronary disease: Scand Cardiovasc J 2006 Jun; 40(3): 152-9
  • Poole-Wilson PA, Kirwan B-A, Vokó Z, de Brouwer S, van Dalen F, Lubsen F. Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs ther. 2006 Feb; 20(1): 45-54
  • B-A Kirwan, J Lubsen, PA Poole-Wilson, on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators: Treatment of angina pectoris: associations with symptom severity. Int J Cardiol. 2005 Feb 15; 98(2): 299-306
  • Lubsen J, Wagener G, Kirwan B-A, de Brouwer S, Poole-Wilson PA on behalf of the ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005 Mar; 23(3): 641-8
  • J Shemesh, N Koren-Morag, S Apter, J Rozenman, B-A Kirwan, Y Itzchak, M Motro: Accelerated Progression of Coronary Calcification: Four-year follow-up in Patients with Stable Coronary Artery Disease: Radiology 2004; 233: 201-209
  • Poole-Wilson PA, Lubsen J, Kirwan, BA et al on behalf of the ACTION investigators: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial: Lancet 2004; Sep 4-10; 364 (99437): 849-57
  • Tim C Clayton, Jacobus Lubsen, Stuart J Pocock, Zoltán Vokó, Bridget-Anne Kirwan, Keith A A Fox, Philip A Poole-Wilson, on behalf of the ACTION investigators: Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients: BMJ 2001; 323: 75-81
  • Lubsen J, Poole-Wilson PA, Pocock SJ, van Dalen FJ, Baumann J, Kirwan B-A, Parker AB – Design and current status of ACTION: A Coronary disease Trial Investigating Outcome with Nifedipine GITS: Eur Heart J 1998 Aug:19 (suppl 1): 120-132
  • JE Otterstad, J Lubsen, A Parker, Kirwan B-A, Ted Plappert, Martin G St John Sutton: Left Ventricular Remodelling in Post–myocardial Infarction patients with Left Ventricular Ejection Fraction 40-50% vs 25-39%: Influence of nisoldipine treatment?: Scand Cardiovasc J 1999 33; 234-241
  • Lubsen J, Kirwan B-A. Combined end-points: Can we use them? (Statist. Med. 2002; 21: 2959-2970)
  • Serruys, P. W., W Rutsch, GR Heyndrickx, N Danchin, EG Mast, W Wijns et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 84.4(1991): 1568-80
  • Lewis, B. S., et al. Left ventricular systolic and diastolic function, and exercise capacity six to eight weeks after acute myocardial infarction. The DEFIANT Study Group. Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy. Am.J.Cardiol. 72.2 (1993): 149-53
  • The DEFIANT-II Research Group: Improved diastolic function with the calcium antagonist nisoldipine (coat-core) in patients post myocardial infarction: results of the DEFIANT study. Doppler Flow and Echocardiography in Functional cardiac Insufficiency: Assessment of Nisoldipine Therapy. Eur.Heart J. 13.11(1992): 1496-505
  • The DEFIANT-II Research Group. Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Results of the DEFIANT-II Study. Eur.Heart J. 18.1 (1997): 31-40
  • Otterstad, J. E., et al. Left ventricular remodelling in post-myocardial infarction patients with left ventricular ejection fraction 40-50% vs 25-39%. Influence of nisoldipine treatment? An echocardiographic substudy from the DEFIANT II study. Scand Cardiovasc J 33.4(1999): 234-41
  • Dumont, J. M. Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS). Control Clin.Trials 14.3(1993): 209-28
  • MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344.8923(1994): 633-38
  • Faxon, D. P. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J.Am.Coll.Cardiol. 25.2(1995): 362-69
  • Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 86.1(1992): 100-10
  • Lubsen, J., et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 76.3(1996): 223-31
  • Fox, K., et al. The effects of nisoldipine on the total ischaemic burden: the results of the ROCKET study. Eur.Heart J. 12.12(1991): 1283-87
  • De Feyter P, Serruys P, Davies M, Richardson P, Lubsen J, Oliver M. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Circulation 1991; 84: 412-423
  • Lubsen J, Pocock S. Factorial trials in cardiology: pros and cons. Eur Heart J 1994; 15: 585-588
  • Lubsen J. Exercise testing as outcome in congestive heart failure trials: design considerations when interpreting results. Drugs 1994; 47: 25-30
  • MacNeill AB, Lubsen J. Multi-centre trials: design and conduct. In: Ardissino D, Savonitto S, Opie LH., eds. Drug Evaluation in Angina Pectoris, 1994
  • Dumont J-M, Mpyisi S, Lubsen J. The clinical development of anti-atherosclerotic therapy: a trialist’s view. In Koenig W ed. Proceedings international symposium on current aspects in atherosclerosis: from a qualitative to a quantitative approach (Ulm, May 14-15, 1993), Blackwell, 1994
  • Hoes AW, Grobbee DE, Lubsen J, Man in’t Veld AJ, van der Does E, Hofman A. Diuretics, beta-blockers and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123: 481-487
  • Hoes AW, Grobbee DE, Lubsen J. >Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995; 13: 805-811
  • Lubsen J, Chadha DR, Yotof YT, Swedberg K. Meta-analysis of five exercise capacity trials in chronic congestive heart failure: effect of ramipril on mortality and morbidity. Am J Cardiol 1996; 77: 1191-1196
  • St John Sutton M, Otterstadt JE, Plappert T, Parker A, Sekarski D, Keane MG, Poole-Wilson P, Lubsen K. Quantitation of left ventricular volumes and ejection fraction in post-infarction patients from biplane and single plane two-dimensional echocardiograms. A prospective study of 371 patients. Eur Heart J 1998; 19: 808-816
  • Lubsen J. The calcium channel antagonist debate: recent developments. Eur Heart J 1998; 19 (Suppl I): I3-I7
  • Feenstra J, Lubsen J, Grobbee DE, Stricker BCh. Heart failure treatments: issues of safety versus issues of quality of life. Drug Safety 1999; 20: 1-7
  • Lubsen J, Hoes AW, Grobbee DE. Implications of trial results: the potentially misleading concepts of 'number-needed-to-treat' and 'average duration of life gained'. Lancet (accepted for publication) Lubsen J, Hoes AW, Grobbee DE. Implications of trial results: the potentially misleading concepts of 'number-needed-to-treat' and 'average duration of life gained. Lancet (accepted for publication)

Selected posters and oral abstracts prepared by SOCAR Research and presented at scientific meetings:

  • Martin St. John Sutton, Bridget-Anne Kirwan, Sophie de Brouwer, Jacobus Lubsen, Philip A Poole-Wilson, JE Otterstad. Women and Coronary Artery Disease: The predictive value of echo cardiographic measurements on outcome: Data from the ACTION trial. Presented as an oral abstract at the American Cardiology of College (ACC) meeting, November 2008.
  • B-A Kirwan, Z Vokó, S de Brouwer, N Danchin, JE Otterstad, PHJM Dunselman, J Lubsen, PA Poole-Wilson, for the ACTION investigators: Effects of 'proven' secondary preventive treatments in patients with stable angina: observational evidence from a large data base. Poster presented by SOCAR at the European Society of Cardiology meeting, Vienna, 2007.
  • B-A Kirwan, Z Vokó, S de Brouwer, PA Poole-Wilson, J Lubsen, for the ACTION investigators: Use of 'proven' secondary preventive medications and determinants of medication changes during prolonged follow-up of a large data base of patients with stable angina. ESC meeting, Poster presented by SOCAR at the European Society of Cardiology meeting Vienna, 2007.
  • P.A. Poole-Wilson, J-E. Otterstad, B-A. Kirwan, Z. Vokó, S. de Brouwer, J. Lubsen, G. Sutton: Clinical events preceding the development of heart failure in patients with stable angina pectoris. Poster presented by SOCAR at the European Society of Cardiology meeting, Barcelona 2006.
  • J. Lubsen, Z. Voko, PA. Poole-Wilson, B-A. Kirwan, S. De Brouwer on behalf of the ACTION investigators. Fall of systolic blood pressure corrected for regression-to-the-mean in the ACTION trial was related to reduction of stroke and heart failure but not to coronary interventions. Poster presented by SOCAR at the European Society of Cardiology meeting, Barcelona 2006.
  • Jan Erik Otterstad, Bridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, Keith A.A. Fox; Pernille Corell, Philip A. Poole-Wilson on behalf of the ACTION investigators: Incidence and outcome of Atrial Fibrillation in Stable Symptomatic Coronary Disease. Poster presented by SOCAR at the European Society of Cardiology meeting, Barcelona, 2006.
  • Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA: Effect of long-acting nifedipine on blood pressure control and clinical outcome in patients with stable angina: the ACTION study. Poster presented by SOCAR at the American Society of Hypertension meeting in San Francisco, May 2005.
  • Jonkers PR, Kirwan BA, Lubsen J: Streamlining the processing of large volumes of paper case report forms. Poster presented by SOCAR at the Society for Clinical Trials meeting, April 2000, Toronto.
  • Kirwan B-A, J Lubsen: Uniform diagnostic classification of Clinical Events in large clinical trials: A practical approach to collecting data. Poster presented by SOCAR at the Society for Clinical Trials meeting, April 2000, Toronto.
  • Motro M, Shemesh J, Kirwan B-A: Prevalence of coronary calcification in relation to age, gender and risk factor profile within the ACTION population. Poster presented by SOCAR at the European Society of Cardiology meeting, Barcelona, 1999.
  • St. John Sutton M, Poole-Wilson PA, Sekarski D, Kirwan B-A. Variability of echocardiographic ejection fraction at investigators sites versus core laboratory in the ACTION study – impact on patient selection. Poster presented by SOCAR at the European Society of Cardiology meeting, Stockholm 1997.
  • Ramsey LE, Kirwan B-A. A comparison of cough in hypertensive patients receiving Telmisartan, Enalapril or hydrochlorothiazide. Poster presented by SOCAR at the European Society of Hypertension meeting in 1996.

Selected list of SOCAR publications and presentations
Contact Careers Privacy Policy Terms of Use Site Map  e-SOCDAT™ 
© 2014 SOCAR Research SA. All rights reserved. Website developed by SOCAR Research SA.